Paul Varley is our Chief Development Officer where he oversees our development processes including Pre-clinical Development, Toxicology, Chemistry Manufacturing and Control (CMC) and Quality.

Prior to joining Alchemab, Paul held similar roles at Kymab, Ltd., AstraZeneca/MedImmune and Cambridge Antibody Technology. Paul also worked at British Biotech, the UK National Institute of Biological Standards and Control (NIBSC) and the U.S. National Institutes of Health. 

Paul is a former member of the British Pharmacopeia (BP) Commission and Chair of BP Expert Advisory Group on Biological and Biotechnological Products. He currently chairs a MHRA/BP Medicines working party on new standards for Biological Medicines (DPS) and is also a member of the European Pharmacopeia (EP) Expert Committee on Monoclonal Antibodies. Paul is also a member of the UK Vaccine Task Force/BIA Manufacturing Advisory Group.

Paul earned a PhD in Biochemistry from the University of Newcastle upon Tyne and a BSc degree in Biomolecular Sciences (First Class) from Portsmouth Polytechnic.